{"id":816336,"date":"2025-02-21T13:50:19","date_gmt":"2025-02-21T18:50:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/"},"modified":"2025-02-21T13:50:19","modified_gmt":"2025-02-21T18:50:19","slug":"intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/","title":{"rendered":"Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA"},"content":{"rendered":"
\n

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc.<\/strong> (“Intellia” or the “Company”) (NASDAQ: NTLA) of a class action securities lawsuit.<\/p>\n

\n CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n

\n https:\/\/zlk.com\/pslra-1\/intellia-therapeutics-inc-lawsuit-submission-form?prid=130901&wire=3<\/a>\n <\/p>\n

\n NTLA<\/strong> investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n

\n CASE DETAILS: <\/strong>According to the complaint, defendants provided investors with material information concerning Intellia’s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants\u2019 statements included, among other things, confidence in the Company\u2019s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. The truth emerged on January 9, 2025, when Intellia published a press release announcing Company reorganization. In pertinent part, defendants disclosed that Intellia would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia\u2019s resources on other pharmaceutical development and would be implementing cost saving in the form of a major reduction in force. As a result, defendants pipeline priority readjustment resulted in the Company\u2019s once-touted NTLA-3001\u2019s discontinuation. Following this news, Intellia\u2019s stock price fell from a closing market price of $12.02 per share on January 8, 2025 to $10.20 per share on January 10, 2025.<\/p>\n

\n WHAT’S NEXT? <\/strong>If you suffered a loss in Intellia during the relevant time frame, you have until April 14, 2025<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

\n NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.<\/strong><\/p>\n

\n WHY LEVI & KORSINSKY: <\/strong>Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

\n CONTACT:<\/strong>
\n
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com<\/a>\u00a0
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/intellia-therapeutics-inc-lawsuit-submission-form?prid=130901&wire=3 NTLA investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia’s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency … <\/p>\n

Continue reading “Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816336","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIntellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/intellia-therapeutics-inc-lawsuit-submission-form?prid=130901&wire=3 NTLA investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia’s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency … Continue reading "Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-21T18:50:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA\",\"datePublished\":\"2025-02-21T18:50:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/\"},\"wordCount\":522,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/\",\"name\":\"Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=\",\"datePublished\":\"2025-02-21T18:50:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA - Market Newsdesk","og_description":"NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/intellia-therapeutics-inc-lawsuit-submission-form?prid=130901&wire=3 NTLA investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia’s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency … Continue reading \"Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-21T18:50:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA","datePublished":"2025-02-21T18:50:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/"},"wordCount":522,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/","name":"Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=","datePublished":"2025-02-21T18:50:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA4MSM2NzYxMzkzIzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-april-14-2025-to-discuss-your-rights-ntla-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights \u2013 NTLA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816336"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816336\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}